ClinicalTrials.gg
CompletedNCT01433510GRAALUpdated May 29, 2024

Tolerability of Grazax in Patients With Hayfever in Real Life Settings

A Phase 4 interventional study of Grazax in Allergic Rhinoconjunctivitis, sponsored by ALK-Abelló A/S. Completed at 1 site in France. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-05-29.

Sponsored by ALK-Abelló A/S · Phase 4, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
628
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Study summary

The purpose of this study is to assess the safety profile of specific immunotherapy with Grazax for three consecutive grass pollen seasons.

Read the detailed description

To assess the safety profile with Grazax according to the presence or not of polysensitization and/or asthma at enrollment

02

Conditions studied

  • Allergic Rhinoconjunctivitis

Keywords

  • Allergic
  • Rhinoconjunctivitis
  • Immunotherapy
03

In context

Lead sponsor

ALK-Abelló A/S is the lead sponsor of 67 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of grass pollen allergy
  • Positive skin prick-test and/or positive specific IgE to grass

Exclusion criteria

Exclusion Criteria:

  • Severe, unstable or uncontrolled asthma (\<70% of predicted value)
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
628 participants (actual)

Study arms

  • Experimental
    Grazax Tablets 75000 SQT

    Timothy Extract

    Drug: Grazax

Interventions

  • DrugGrazax

    1 tablet/day - pre and co-seasonal

06

What researchers measure

Primary outcomes

  1. Adverse Events related to Grazax

    All adverse events were reported according to the MedDRA dictionary

    Time frame: From November 2007 to October 2010 (3 years)

07

Study locations

1 site
  • Centre Hospitalier Universitaire
    Nantes, 44000, France
08

References and documents

Publications

  • Wessel F, Chartier A, Meunier JP, Magnan A. Safety and tolerability of an SQ-standardized GRAss ALlergy immunotherapy tablet (GRAZAX(R)) in a real-life setting for three consecutive seasons - the GRAAL trial. Clin Drug Investig. 2012 Jul 1;32(7):451-63. doi: 10.2165/11634270-000000000-00000. PubMed 22594491 ↗
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Nov 2007, a primary completion of Oct 2010 and a completion of Dec 2010. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 12, 2011
First posted
Sep 14, 2011
Start
Nov 2007
Primary completionActual
Oct 2010
CompletionActual
Dec 2010
Last update
May 29, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433510
Lead sponsor
ALK-Abelló A/S
Responsible party
Sponsor
First posted
Sep 14, 2011
Start date
Nov 2007
Primary completion
Oct 2010
Completion
Dec 2010
Last update
May 29, 2024

Study contacts

François FW Wessel, MD
principal investigator · Centre Hospitalier Universitaire F-44000 Nantes

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Grazax

Start the discussion